Loading
Hormone-blocking treatments for prostate and breast cancer, taken for years, raise the risk of diabetes, heart disease and bone fractures. Survivors on these drugs should get the same preventive care as diabetics.
Androgen deprivation therapy increases diabetes, cardiovascular events, and fractures; aromatase inhibitors affect bone and lipids. Millions of survivors take these drugs for years, but cardiometabolic risk management is rarely owned by anyone. A protocolised pathway with baseline and annual metabolic and bone assessment, and treatment to targets, delivered by nurses or pharmacists, would prevent a substantial burden of non-cancer morbidity.
Shares Report death from other causes as an outcome of the prostate cancer service, split by deprivation and ethnicity, Survivorship and late effects are neglected, HR-positive / HER2-negative breast cancer, Prostate cancer.
Shares Hormonal therapy roadmap: removing the ovaries → tamoxifen → oral degraders switched by a blood test, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
Shares Older and multimorbid patients are excluded and undertreated, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
Shares Association of Black race with prostate cancer-specific and other-cause mortality, Report death from other causes as an outcome of the prostate cancer service, split by deprivation and ethnicity, Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch, Prostate cancer.
Shares Hormonal therapy roadmap: removing the ovaries → tamoxifen → oral degraders switched by a blood test, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
Shares Report death from other causes as an outcome of the prostate cancer service, split by deprivation and ethnicity, Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch, Prostate cancer.
Shares Hormonal therapy roadmap: removing the ovaries → tamoxifen → oral degraders switched by a blood test, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
Shares Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer, Prostate cancer.